Literature DB >> 21802119

Robotic-assisted radical prostatectomy decreases the incidence and morbidity of surgical site infections.

Matthew K Tollefson1, Igor Frank, Matthew T Gettman.   

Abstract

OBJECTIVE: To determine the incidence and morbidity of surgical site infections (SSI) during prostatectomy, and determine the association with surgical approach. The development of a SSI after radical prostatectomy is associated with increased cost and significant morbidity. However, existing comparisons between open and robotic surgery have been made comparing a contemporary robotic experience with historical cohorts undergoing open surgery.
METHODS: We reviewed the incidence of SSI in 5908 consecutive patients undergoing both retropubic radical prostatectomy (RRP; n = 4824 [81.7%]) and robotic-assisted radical prostatectomy (RARP; n = 1084 [18.3%]) at our institution between 2004 and 2008. Patient records were reviewed for the development and treatment of an SSI, defined as wound erythema or cellulitis that necessitated antibiotic therapy or opening of the surgical wound within 30 days of surgery.
RESULTS: In total, 222 (3.7%) patients developed an SSI. Those undergoing RARP (6/1084, 0.6%) were significantly less likely to develop an SSI than patients undergoing RRP (216/4824, 4.5%) (P <.001). Furthermore, SSIs in patients undergoing RARP resolved more quickly (median, 7 vs 16 days) and were less likely to require wound incision and/or drainage (1 vs 84 patients), hospital readmission (0 vs 11 patients), or return to the operating room for debridement (0 vs 6 patients).
CONCLUSIONS: Patients undergoing RARP are less likely to develop SSIs than patients undergoing RRP. Furthermore, the infections that develop after minimally invasive surgery are less severe. Continued investigation into the mechanisms of SSIs are needed to further decrease patient morbidity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21802119     DOI: 10.1016/j.urology.2011.05.037

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Utilization of a novel valveless trocar system during robotic-assisted laparoscopic prostatectomy.

Authors:  Arvin K George; Reinhard Wimhofer; Kate V Viola; Markus Pernegger; Walter Costamoling; Louis R Kavoussi; Wolfgang Loidl
Journal:  World J Urol       Date:  2015-03-01       Impact factor: 4.226

2.  Surgical site infections after radical prostatectomy: A comparative study between robot-assisted laparoscopic radical prostatectomy and retropubic radical prostatectomy.

Authors:  Daniar K Osmonov; Amr A Faddan; Alexey V Aksenov; Carsten M Naumann; Leonid M Rapoport; Evgeny A Bezrukov; Dmitry G Tsarichenko; Klaus P Jünemann
Journal:  Turk J Urol       Date:  2018-07

3.  Predictors and costs of surgical site infections in patients with endometrial cancer.

Authors:  Jamie N Bakkum-Gamez; Sean C Dowdy; Bijan J Borah; Lindsey R Haas; Andrea Mariani; Janice R Martin; Amy L Weaver; Michaela E McGree; William A Cliby; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2013-04-02       Impact factor: 5.482

4.  Multidetector CT imaging of post-robot-assisted laparoscopic radical prostatectomy complications.

Authors:  Massimo Tonolini; Federica Villa; Roberto Bianco
Journal:  Insights Imaging       Date:  2013-09-10

5.  Long-term adverse effects after retropubic and robot-assisted radical prostatectomy. Nationwide, population-based study.

Authors:  Jón Örn Fridriksson; Yasin Folkvaljon; Karl-Johan Lundström; David Robinson; Stefan Carlsson; Pär Stattin
Journal:  J Surg Oncol       Date:  2017-06-07       Impact factor: 3.454

6.  Evaluation of Surgical Site Infection in Mini-invasive Urological Surgery.

Authors:  Jacopo Adolfo Rossi de Vermandois; Giovanni Cochetti; Michele Del Zingaro; Alberto Santoro; Mattia Panciarola; Andrea Boni; Matteo Marsico; Gianluca Gaudio; Alessio Paladini; Paolo Guiggi; Roberto Cirocchi; Ettore Mearini
Journal:  Open Med (Wars)       Date:  2019-09-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.